Combining AR-targeted therapies with agents that selectively disrupt ERG function or its downstream pathways provides potential synergistic options for treating TMPRSS2:ERG fusion-positive PCa (81). The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.